This triple therapeutic strategy is of translational relevance as a phase I trial (NCT03961971) for recurrent GBM patients in evaluating the safety of stereotactic radiosurgery, spartalizumab (anti-PD-1), and MBG453 (anti-TIM-3) combination treatment is underway. Here, PDCD1 is linked to glioblastoma.